We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer
Background : Patient-level data from 2 phase III studies in patients with previously untreated , advanced-stage , nonsquamous non – small cell lung cancer ( NSCLC ) were pooled to examine outcomes with bevacizumab and chemotherapy based on age . Methods : Data from patients r and omized to paclitaxel – carboplatin (PC)+bevacizumab in the Eastern Cooperative Oncology Group 4599 ( E4599 ) and PointBreak studies were pooled and compared with E4599 patients r and omized to PC alone . Patients were grouped by age : below 65 , 65 to 74 , 70 to 74 , below 75 , and 75 years or above . A multivariable model was used to calculate hazard ratios ( HRs ) and corresponding 95 % confidence intervals ( CIs ) using time-to-event outcomes . Adverse events ( AEs ) were assessed by age group in each study . Results : The PC+bevacizumab and PC arms comprised 901 and 444 patients , respectively . PC+bevacizumab was associated with significant increases in overall survival relative to PC in patients below 65 years ( hazards ratio [ HR ] , 0.75 ; 95 % confidence interval [ CI ] , 0.62 - 0.89 ) , 65 to 74 years ( HR , 0.80 ; 95 % CI , 0.64 - 1.00 ) , 70 to 74 years ( HR , 0.68 ; 95 % CI , 0.48 - 0.96 ) , and below 75 years ( HR , 0.78 ; 95 % CI , 0.68 - 0.89 ) but not in those aged 75 years or above ( HR , 1.05 ; 95 % CI , 0.70 - 1.57 ) . Increased incidence of grade ≥3 AEs was reported with PC+bevacizumab versus PC in patients below 75 years ( 63 % vs. 48 % ; P<0.05 ) and 75 years or above ( 81 % vs. 56 % ; P < 0.05 ) in E4599 . Conclusions : This analysis suggests that the survival benefits  associated with PC+bevacizumab extend to patient subgroups below 75 years with advanced-stage NSCLC ; no benefit , however , was observed for bevacizumab-eligible patients who were 75 years or above
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV